Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person has voluntarily agreed to take part and has signed a consent form.
- The person is between 18 and 75 years old.
- The person has a laboratory-confirmed diagnosis of high-grade mainly serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; or a moderately or poorly differentiated type of ovarian cancer called endometrioid adenocarcinoma.
- The person has previously received 2 to 3 rounds of platinum-based chemotherapy, achieved a complete or partial response, and the cancer did not return for at least 6 months after the second-to-last platinum-based treatment.
- People who have previously been treated with a drug called bevacizumab are eligible.
- Previous treatment with PARP inhibitor medicines (other than Fluzoparib specifically) is permitted.
- The person has a general health/activity score of 0 or 1 on a standard medical scale (meaning they are fully active or have only minor restrictions on physical activity).
- The person's blood counts and organ function meet specific minimum requirements, as measured by blood tests — including healthy enough levels of white blood cells, platelets, haemoglobin, albumin, liver enzymes, and kidney function (confirm exact values with trial site; no blood transfusions or growth factor injections are permitted within 14 days before the qualifying tests).
- People who could become pregnant must use an approved contraceptive method during treatment and for a set period after the last dose; must have a negative pregnancy test within 72 hours before joining; and must not be breastfeeding.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person has had another cancer (other than certain treated skin, thyroid, cervical, or breast cancers meeting specific criteria) within the past 5 years, or currently has another untreated cancer.
- The person has cancer that has spread to the brain or central nervous system and has not been treated.
- The person is unable to swallow tablets normally, or has a digestive condition that the researchers believe may interfere with how the study drugs are absorbed.
- The person has experienced a bowel obstruction within the past 3 months.
- The person has fluid build-up related to cancer (in the abdomen or around the lungs) that is causing symptoms and requires draining, or has had such drainage within 2 months before starting the trial.
- The person has heart problems that are not well controlled, including moderate-to-severe heart failure, unstable chest pain, a heart attack within the past year, certain abnormal heart rhythms requiring treatment, or a specific abnormal heart electrical reading (QTc greater than 470ms).
- The person has abnormal blood clotting results or a tendency to bleed, or is currently receiving clot-dissolving or blood-thinning therapy (low-dose preventive heparin or aspirin may be permitted — confirm with trial site).
- The person has an active infection or an unexplained fever above 38.5°C during the screening period or before the first dose.
- The person has a condition that weakens the immune system (such as HIV), or has active hepatitis B or hepatitis C meeting specific test thresholds.
- The person finished a previous cancer treatment (such as chemotherapy, radiotherapy, hormone therapy, or targeted therapy) less than 4 weeks before joining, or still has side effects from previous treatment that have not returned to a mild level (except for hair loss).
- The person has taken part in another clinical drug trial within the past 4 weeks.
- The person is expected to need other systemic (whole-body) cancer treatments during the study period.
- The person has a known allergy to Fluzoparib, apatinib, or any of their ingredients.
- In the opinion of the investigator, the person has other circumstances that could make continuing the study unsafe or unreliable, such as serious medical or mental health conditions, significantly abnormal test results, or personal or family circumstances affecting safety or data collection.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Progression Free Survival(PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.